The $66 billion deal would create one of the top 10 global pharmaceutical companies by revenue. The deal comes after Allergan was faced with an unwanted takeover from Valeant in April, which was valued at $54 billion.

With this size, this acquisition would be one of the largest deals made in 2014.

This deal adds to the many major acquisitions that have already taken place in 2014 and is likely to be one of the biggest acquisitions this year. Major news events are very important for mutual fund investors to be aware of – even if the funds you own only have a small stake in the affected companies.